GS Paper: Health, Vaccines and Biotechnology

Why in the News?

An International Centre for Genetic Engineering and Biotechnology (ICGEB) scientist has argued that timely and fair global vaccine access for zoonotic outbreaks, such as Ebola, Nipah and hantavirus, requires academia-industry partnerships and a shared risk funding model. This is because such vaccines are not commercially attractive to manufacturers.

Why are zoonotic outbreak vaccines commercially unattractive?

1. Small, unpredictable markets: Ebola, Nipah and hantavirus outbreaks are episodic and geographically concentrated, giving manufacturers no stable, predictable market to justify sustained investment.
2. High development cost, low return: Vaccine development costs remain similar regardless of market size, so a vaccine with a small addressable market offers manufacturers a poor return relative to vaccines for widespread diseases.
3. Outbreak timing mismatch: Vaccine demand spikes only during an active outbreak, while development must happen years in advance, a mismatch that discourages manufacturers from investing ahead of demonstrated demand.

What would a shared risk funding model change?

1. Risk redistribution: A shared risk funding model spreads the financial risk of vaccine development across academia, industry and public funders, rather than leaving it entirely on a manufacturer’s commercial judgment.
2. Academia-industry partnership: Academic institutions like ICGEB can carry early stage research risk, handing over a de-risked candidate for industry to scale, lowering the barrier for private investment.
3. Access consequence: A funding model that does not depend on commercial viability alone can keep resulting vaccines priced for equitable global access rather than for cost recovery in a niche market.

Conclusion

The central idea is that zoonotic outbreak vaccines fail a commercial viability test that has nothing to do with their public health importance. A shared risk funding model, built on academia-industry partnership, is the mechanism proposed to close that gap between epidemic risk and market incentive.

Back2Basics

International Centre for Genetic Engineering and Biotechnology (ICGEB): An intergovernmental organisation with a component in New Delhi, conducting research in genetic engineering and biotechnology, including vaccine and infectious disease research.

PYQ Relevance

[UPSC 2022] What is the basic principle behind vaccine development? How do vaccines work? What approaches were adopted by the Indian vaccine manufacturers to produce COVID-19 vaccines?

Linkage: The PYQ examines the scientific principles of vaccine development and the challenges in developing vaccines for emerging infectious diseases. The article explains why vaccines for zoonotic diseases require shared-risk funding and academia-industry partnerships to overcome weak commercial incentives and ensure equitable access.